Tadao Akizawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5339436/publications.pdf

Version: 2024-02-01

77	3,956	147801	118850
papers	citations	31 h-index	62 g-index

80	80	80	2814
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effectiveness of <scp>SARSâ€CoV</scp>â€2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. Therapeutic Apheresis and Dialysis, 2023, 27, 19-23.	0.9	12
2	Two longâ€term phase 3 studies of enarodustat (<scp>JTZ</scp>â€951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: <scp>SYMPHONY NDâ€Long</scp> and <scp>HDâ€Long</scp> studies. Therapeutic Apheresis and Dialysis, 2022, 26, 345-356.	0.9	13
3	Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japanâ€"A Phase 2 Randomized Trial. Kidney International Reports, 2022, 7, 177-188.	0.8	13
4	Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. Kidney International Reports, 2022, 7, 763-775.	0.8	3
5	Treatment of anemia associated with chronic kidney disease with the <scp>HIF</scp> prolyl hydroxylase inhibitor enarodustat: A review of the evidence. Therapeutic Apheresis and Dialysis, 2022, 26, 679-693.	0.9	7
6	Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. Therapeutic Apheresis and Dialysis, 2022, , .	0.9	3
7	Pharmacokinetic/pharmacodynamic modeling of roxadustat's effect on LDL cholesterol in patients in Japan with dialysis-dependent chronic kidney disease and anemia. Drug Metabolism and Pharmacokinetics, 2022, 46, 100461.	2.2	3
8	Dose-Response of Tenapanor in Patients with Hyperphosphatemia Undergoing Hemodialysis in Japan- A Phase 2 Randomized Trial. Kidney International Reports, 2022, , .	0.8	0
9	Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Therapeutic Apheresis and Dialysis, 2021, 25, 575-585.	0.9	13
10	Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a singleâ€arm, phase 3 study. Therapeutic Apheresis and Dialysis, 2021, 25, 917-925.	0.9	7
11	A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. Kidney International Reports, 2021, 6, 1840-1849.	0.8	22
12	Phase 3 Study of Roxadustat to Treat Anemia in Nonâ€"Dialysis-Dependant CKD. Kidney International Reports, 2021, 6, 1810-1828.	0.8	35
13	A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. Kidney Diseases (Basel, Switzerland), 2021, 7, 494-502.	2.5	21
14	Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a singleâ€arm, openâ€label, phase 3 study. Therapeutic Apheresis and Dialysis, 2021, , .	0.9	8
15	Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis. Kidney International Reports, 2021, 6, 2604-2616.	0.8	22
16	Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. Kidney International Reports, 2021, 6, 2830-2839.	0.8	4
17	Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients. Kidney International Reports, 2021, 6, 2371-2380.	0.8	10
18	Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. American Journal of Nephrology, 2021, 52, 871-883.	3.1	24

#	Article	IF	Citations
19	Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. American Journal of Nephrology, 2021, 52, 884-893.	3.1	22
20	Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Renal Replacement Therapy, 2021, 7, 59.	0.7	34
21	Appreciation for the contribution of the Japanese Society for Dialysis Therapy to development of Therapeutic Apheresis and Dialysis. Therapeutic Apheresis and Dialysis, 2021, 25, 726-726.	0.9	0
22	Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Openâ€Label Study. Therapeutic Apheresis and Dialysis, 2020, 24, 115-125.	0.9	81
23	A 24â€Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. Therapeutic Apheresis and Dialysis, 2020, 24, 108-114.	0.9	36
24	Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis, 2020, 24, 248-257.	0.9	21
25	Oral roxadustat three times weekly in ESAâ€naÃ¯ve and ESAâ€converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. Therapeutic Apheresis and Dialysis, 2020, 24, 628-641.	0.9	51
26	Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1155-1165.	4.5	80
27	Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis . International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 97-106.	1.8	2
28	Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. Journal of the American Society of Nephrology: JASN, 2020, 31, 1628-1639.	6.1	133
29	<scp>COVID</scp>â€19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic Apheresis and Dialysis, 2020, 24, 361-365.	0.9	53
30	A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-NaÃ¯ve Chronic Kidney Disease Patients Not on Dialysis. Nephron, 2020, 144, 372-382.	1.8	48
31	Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. BMJ Open, 2019, 9, e026602.	1.9	18
32	A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. American Journal of Nephrology, 2019, 49, 165-174.	3.1	62
33	Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open, 2019, 9, e026704.	1.9	22
34	Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. Nephron, 2019, 143, 77-85.	1.8	36
35	Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. Scientific Reports, 2019, 9, 6410.	3.3	16
36	Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. American Journal of Nephrology, 2019, 49, 271-280.	3.1	40

#	Article	IF	Citations
37	Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. Clinical and Experimental Nephrology, 2019, 23, 739-748.	1.6	11
38	Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS). BMJ Open, 2019, 9, e031476.	1.9	3
39	Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. Clinical and Experimental Nephrology, 2019, 23, 258-267.	1.6	12
40	Effects of Molidustat in the Treatment of Anemia in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 28-39.	4.5	78
41	NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. Kidney International Reports, 2018, 3, 73-80.	0.8	48
42	Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. Clinical Therapeutics, 2018, 40, 2099-2111.	2.5	14
43	Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clinical Pharmacology: Advances and Applications, 2018, Volume 10, 101-111.	1.2	12
44	Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS ONE, 2018, 13, e0204896.	2.5	18
45	Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clinical Drug Investigation, 2018, 38, 945-954.	2.2	15
46	SP334IRON REGULATION BY MOLIDUSTAT, BAY 85-3934, A DAILY ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2018, 33, i457-i457.	0.7	3
47	A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE, 2018, 13, e0195316.	2.5	50
48	Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney International, 2018, 94, 818-825.	5.2	65
49	Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. Therapeutic Apheresis and Dialysis, 2018, 22, 444-456.	0.9	39
50	Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. American Journal of Nephrology, 2017, 45, 127-135.	3.1	85
51	Membranous glomerulonephropathy in a patient with bullous pemphigoid. CEN Case Reports, 2017, 6, 50-54.	0.9	4
52	Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Clinical and Experimental Nephrology, 2017, 21, 446-456.	1.6	68
53	Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney International, 2017, 91, 227-234.	5.2	93
54	PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Scientific Reports, 2016, 6, 19612.	3.3	47

#	Article	IF	Citations
55	Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clinical and Experimental Nephrology, 2016, 20, 71-76.	1.6	7
56	Myocardial <scp>SPECT</scp> Images in Incident Hemodialysis Patients Without Ischemic Heart Disease. Therapeutic Apheresis and Dialysis, 2015, 19, 575-581.	0.9	1
57	Impacts of Recombinant Human Erythropoietin Treatment During Predialysis Periods on the Progression of Chronic Kidney Disease in a Largeâ€Scale Cohort Study (<scp>C</scp>oâ€<scp>JET</scp>) Tj ETQq1 1 0.784314 rgBT /O	1.9	184
58	Clinical Practice Guideline for the Management of Chronic Kidney Diseaseâ€Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis, 2013, 17, 247-288.	0.9	305
59	Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. Kidney International Supplements, 2013, 3, 436-441.	14.2	15
60	Naturally Occurring Higher Hemoglobin Concentration Does Not Increase Mortality among Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2011, 22, 358-365.	6.1	58
61	2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. Therapeutic Apheresis and Dialysis, 2010, 14, 240-275.	0.9	211
62	Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis, 2008, 12, 117-125.	0.9	29
63	Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrology Dialysis Transplantation, 2008, 23, 3643-3653.	0.7	65
64	Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochemical and Biophysical Research Communications, 2007, 362, 11-16.	2.1	54
65	Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney International, 2005, 67, 1179-1187.	5.2	640
66	The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. British Journal of Clinical Pharmacology, 2004, 57, 726-734.	2.4	36
67	Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). American Journal of Kidney Diseases, 2004, 44, 94-111.	1.9	600
68	Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. American Journal of Kidney Diseases, 2004, 44, 27-33.	1.9	48
69	Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. American Journal of Kidney Diseases, 2004, 44, 27-33.	1.9	78
70	Management of secondary hyperparathyroidism of dialysis patients. Nephrology, 2003, 8, S53-S57.	1.6	9
71	Plasma Exchange for Thrombocytopenia in Antiphospholipid Syndrome: A Case Report. Therapeutic Apheresis and Dialysis, 1998, 2, 157-159.	0.6	10
72	Therapeutic Apheresis for Septic Patients with Organ Dysfunction: Hemoperfusion using a Polymyxin B Immobilized Column. Artificial Organs, 1998, 22, 1038-1044.	1.9	94

#	Article	IF	Citations
73	Therapeutic Apheresis and Therapeutic Plasmapheresis: The Relationship to the Annual Meeting of the Japanese Society for Apheresis. Therapeutic Apheresis and Dialysis, 1997, 1, 307-307.	0.6	0
74	Clinical effect of L-threo-3, 4-dihydroxyphenylserine (L-threo-DOPS) on orthostatic hypotension in hemodialysis patients. A placebocontrolled double-blind study.. Nihon Toseki Igakkai Zasshi, 1997, 30, 941-959.	0.1	0
75	The Effects and Pharmacokinetics of rhG-CSF in Patients with Chronic Renal Failure. Artificial Organs, 1995, 19, 1251-1257.	1.9	11
76	Clinical application of FR-860 to hemodialysis: Multicenter cooperative study in Japan.. Journal of Japanese Society for Dialysis Therapy, 1991, 24, 507-514.	0.0	0
77	Evaluation of ÃŸ₂â€Microglobulin Removal with Highâ€Performance Hemodiafiltration. Artificial Organs, 1988, 12, 11-15.	1.9	6